Analysts have set 12-month price targets for Genmab, revealing an average target of $47.78, a high estimate of $50.00, and a ...
Genmab A/S (Nasdaq: GMAB) will increase its share capital by 6,959 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing ...
Based on strong overall and progression-free survival data in its Phase III confirmatory study, Pfizer and Genmab’s ...
Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024HighlightsThe U.S. Food and Drug Administration (U.S.
Genmab will acquire ProfoundBio for $1.8 billion in cash. The acquisition adds an important antibody drug conjugate ('ADC') platform, a missing piece in Genmab's platform. Genmab plans to ...
Pfizer and Genmab on Monday said they had received full approval from U.S. regulators for their treatment for certain forms of cervical cancer. The companies’ drug Tivdak had previously been ...
Genmab (CPH: GMAB) continues to thrive. The Danish biotech company reported its financial results for the first quarter of 2024 on Thursday, sending shares up by 5% in the following day’s trading.
Company Announcement COPENHAGEN, Denmark; April 22, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 ...
Hello, and welcome to the Genmab First Quarter 2024 Conference Call. As a reminder, this conference call is being recorded. During this telephone conference, you may be presented with forward ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback